+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting an observational study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukemia CLL who received acalabrutinib in the United Kingdom through the Early Access Programme EAP. The study aims to estimate progression-free survival, overall survival, response rates, healthcare resource use, and treatment patterns in these patients. Participants in this study are patients who started first-line treatment with acalabrutinib between April 1, 2020, and April 1, 2021, as part of the UK EAP. The study is non-interventional, meaning no study drug is administered by researchers instead, data are collected retrospectively from patients clinical records according to local laws. During the study, researchers will review clinical data from patient records to measure outcomes such as progression-free survival at multiple time points up to 60 months, overall survival, response rates, and treatment interruptions. The study will provide real-world evidence on acalabrutinib use and outcomes in CLL patients over an average of five years, with no additional treatments or visits required from participants.

Age: 18Years - 130YearsAll Genders
29 locations